Key result
Fluoropyrimidines trigger diverse cardiotoxicity from angina to sudden death, requiring early screening and management.
Why the study?
Fluoropyrimidines are widely used chemotherapeutics that can cause cardiotoxicity ranging from angina pectoris to sudden death.
What are the mechanisms, diagnosis, and management of fluoropyrimidine-induced cardiotoxicity in cancer patients?
What are the mechanisms, diagnosis, and management of fluoropyrimidine-induced cardiotoxicity in cancer patients?
This review provides an overview of fluoropyrimidine-induced cardiotoxicity, a critical issue in cardio-oncology given the widespread use of these chemotherapeutics.
Alerts clinicians to fluoropyrimidine cardiotoxicity manifestations; leaves optimal screening and management strategies open for prospective trials.
Cardio-oncology is a discipline based on early screening, monitoring, and treating chemotherapy-induced cardiotoxicity. There are many chemotherapeutics known for their cardiac toxic effects, including fluoropyrimidines. Fluoropyrimidine represents the cornerstone of many types of cancer and each year almost two million cancer patients undergo this treatment. Fluoropyrimidine-induced cardiotoxicity can be manifested in several forms, from angina pectoris to sudden death. This paper is a review of how the cardiotoxicity of fluoropyrimidines is presented, the mechanisms of its occurrence, its diagnosis, and management.
No takes yet. Share an insight, caveat, or question.
Deac et al. (2020) conducted a review in Fluoropyrimidine-induced cardiotoxicity. Fluoropyrimidines was evaluated. Fluoropyrimidines can induce cardiotoxicity manifesting in several forms, from angina pectoris to sudden death, necessitating early screening, monitoring, and management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: